{"id":"W1999745497","doi":"10.1111/ijcp.12443","title":"OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder","year":2014,"lang":"en","type":"article","venue":"International Journal of Clinical Practice","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Allergan","keywords":"Medicine; Overactive bladder; Anticholinergic; Discontinuation; Placebo; Urination; Urology; Urinary incontinence; Tolterodine; Oxybutynin; Trigone of urinary bladder; Adverse effect; Urinary system; Solifenacin; Internal medicine; Anesthesia; Urinary bladder","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002999789,0.0006651313,0.0025578,0.0005025125,0.0001901191,0.0007855424,0.0003627738,0.0005401321,0.002772216],"category_scores_gemma":[0.00284776,0.0003024983,0.003373594,0.0003866118,0.0002890209,0.0003340142,0.0003151664,0.0006653985,0.0001355789],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005174539,"about_ca_system_score_gemma":0.0005139048,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005841274,"about_ca_topic_score_gemma":0.002189014,"domain_scores_codex":[0.9989195,0.0006210514,0.0001454009,0.0001124766,0.000129589,0.00007204167],"domain_scores_gemma":[0.998637,0.0005085493,0.0006157081,0.00006298805,0.00008635347,0.00008935465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5839349,0.00309688,0.01439859,0.02575541,0.07718358,0.0001530951,0.0001628202,0.001056062,0.02272532,0.0001376901,0.001533141,0.2698625],"study_design_scores_gemma":[0.4833571,0.2365927,0.1469254,0.003995837,0.1102562,0.0006997883,0.0002405449,0.001223956,0.009978813,0.0003565105,0.006290802,0.00008230896],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.854117,0.1404642,0.0007021677,0.0007711753,0.0003038982,0.0008159765,0.0006213083,0.00008622429,0.002118175],"genre_scores_gemma":[0.9749966,0.02270879,0.0006593526,0.000374309,0.0001981792,0.0002599269,0.0003163348,0.000008388894,0.0004781765],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002999789,"threshold_uncertainty_score":0.01586455,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03376758209583948,"score_gpt":0.4141585933161128,"score_spread":0.3803910112202734,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}